Skip to content
Screener

Bausch + Lomb BLCO Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

HRO
HarrowHROW
-$355K0.0%
AbbVie logo
AbbVieABBV
$44M+4.8%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$977M+3.6%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO

Other financials

Income statement

See full
Revenue$1.4B+9.1%
Operating income$83.0M+855%
Net income-$14.0M+77.4%
EPS (diluted)-$0.04+77.8%

Balance sheet

See full
Cash & equivalents$378.0M+39.0%
Total debt$5.1B+2.4%
Total equity$6.4B-1.0%
Total assets$13.9B+0.2%

Cash flow

See full
Operating cash flow$153.0M+337%
CapEx$71.0M-20.2%
Free cash flow$82.0M+252%

Valuation

See full
Market cap$5.99B+24.2%
Enterprise value$10.69B+12.4%
P/S1.1×+0.1×

Profitability

See full
Operating margin6.1%+5.3pp
Net margin-3.2%-1.0pp
FCF margin-3.4%0.0pp

Returns & leverage

See full
Return on equity-2.7%-0.7pp
Debt / equity0.8×0.0×
Current ratio1.5×0.0×

Where this comes from

Reported directly by Bausch + Lomb in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The source filing: Bausch + Lomb’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001860742-26-000088
Line itemJune 30, 2026December 31, 2025
Common shares, no par value, unlimited shares authorized, 357,057,005 and 354,209,319 issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital8,6108,563
Accumulated deficit(1,016)(931)
Accumulated other comprehensive loss(1,218)(1,184)
Total Bausch + Lomb Corporation shareholders’ equity6,3766,448
Noncontrolling interest6871
Total equity6,4446,519
Total liabilities and equity$13,859$14,022

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Bausch + Lomb's noncontrolling interests in subsidiaries?
Bausch + Lomb (BLCO) reported noncontrolling interests in subsidiaries of $68M in Q2 2026.
How has Bausch + Lomb's noncontrolling interests in subsidiaries changed year-over-year?
Bausch + Lomb's noncontrolling interests in subsidiaries decreased by 0.0% year-over-year, from $68M to $68M.
What is the long-term trend for Bausch + Lomb's noncontrolling interests in subsidiaries?
Over 4 years (2021 to 2025), Bausch + Lomb's noncontrolling interests in subsidiaries has grown at a -0.7% compound annual growth rate (CAGR), from $73M to $71M.
What does noncontrolling interests in subsidiaries mean?
This represents the portion of a subsidiary's net assets that is owned by outside shareholders rather than the parent company. It is reported within equity to show the total value of the subsidiary's assets and liabilities that are not attributable to the parent. It reflects the non-controlling stake in consolidated entities.

Ask your AI about Bausch + Lomb's noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude